The negative impact of pretreatment anemia (using a Hb level threshold of 9–14.5 g/dL) on locoregional control and survival has been consistently documented in patients with various solid tumors (e.g., head and neck, uterine cervix, lung, anus, and prostate) [33]. Here, GSTM1 is linked to anemia (phenotype).